newsfilter
← Latest News
GlobeNewswire·

Vera Therapeutics to Host ASN Kidney Week Investor Webcast and Third Quarter 2026 Financial Results Conference Webcast

VERA
  • Vera Therapeutics will host an investor webcast on October 22, 2026, at 4:30 p.m. ET to discuss final efficacy results from the ORIGIN 3 trial of TRUTAKNA (atacicept-vymj) presented at ASN Kidney Week 2026.
  • The company will host a second investor webcast on November 5, 2026, at 4:30 p.m. ET to review Q3 2026 financial results & business updates.
  • Dr. Jonathan Barratt from the University of Leicester will join management to present data on TRUTAKNA for IgA nephropathy (IgAN) during the October 22 session.
  • TRUTAKNA is approved under accelerated approval to reduce proteinuria in adults with primary IgAN at risk for disease progression, though long-term kidney function decline benefits require confirmation.
  • TRUTAKNA is contraindicated in patients with serious hypersensitivity to atacicept-vymj or any excipients.
  • Immunosuppression is a key warning, as the drug reduces antibody production & increases infection risk, with infections reported in 32% of patients vs 28% of placebo patients in trials.
  • Live vaccines are not recommended within 30 days prior to initiation or during treatment due to potential interference with immune responses.
  • The most common adverse reactions (≥5%) were infections (32%) & local administration reactions (30%), including injection site reactions & erythema.
  • Safety & effectiveness in pediatric patients have not been established, & insufficient data exists regarding use in pregnant women.
  • TRUTAKNA is a self-administered once-weekly autoinjector that inhibits BAFF & APRIL cytokines to target B-cell activation in IgAN.
  • The TRUTAKNA TRU SUPPORT program offers insurance assistance, financial aid, & educational resources, with eligible commercially insured patients potentially paying $0 out of pocket.
  • IgA nephropathy is a progressive immune-mediated kidney disease affecting approximately 2.5 adults per 100,000 globally, often leading to kidney failure within 10 to 20 years.
  • Vera Therapeutics is a commercial-stage biotechnology company based in Brisbane, California, focused on autoimmune diseases & founded in 2016.